VR Adviser’s Ventyx Biosciences VTYX Stock Holding History

VR Adviser’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-207,925	Closed	-$7.26M	–	35
2022 Q3	$7.26M	Buy	+207,925	New	+$4.6M	1.12%	20

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VR Adviser's VTYX Position: Q4 2022 in Review

VR Adviser sold out of Ventyx Biosciences (VTYX) in Q4 2022, closing a stake of 207,925 shares — an estimated $7.26M sold.

VR Adviser first reported a position in VTYX in Q3 2022 and held it in 1 quarter. The position peaked at $7.26M in Q3 2022. 125 funds tracked by Wall St. Rank hold VTYX as of Q4 2022.

VR Adviser reported no remaining Ventyx Biosciences position as of Q4 2022 after selling out during the quarter.
VR Adviser sold 207,925 Ventyx Biosciences shares in Q4 2022, an estimated $7.26M.
VR Adviser first reported a position in Ventyx Biosciences in Q3 2022 and held it in 1 quarter.
VR Adviser's Ventyx Biosciences position peaked at $7.26M in Q3 2022.
125 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2022.

Based on VR Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.